Pediatric Vaccines Market (By Type: Monovalent, Multivalent; By Technology: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines; By Indication: Varicella, Human Papilloma Virus, Measles, Mumps & Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rotavirus, Diphtheria, Pertussis & Tetanus, Influenza, Other Indications) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pediatric Vaccines Market
5.1. COVID-19 Landscape: Pediatric Vaccines Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pediatric Vaccines Market, By Type
8.1. Pediatric Vaccines Market, By Type, 2024-2033
8.1.1 Monovalent
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Multivalent
8.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Pediatric Vaccines Market, By Technology
9.1. Pediatric Vaccines Market, By Technology, 2024-2033
9.1.1. Live Attenuated Vaccines
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Inactivated Vaccines
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Toxoid Vaccines
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Pediatric Vaccines Market, By Indication
10.1. Pediatric Vaccines Market, By Indication, 2024-2033
10.1.1. Varicella
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Human Papilloma Virus
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Measles, Mumps & Rubella
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Meningococcal Disease
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Pneumococcal Disease
10.1.5.1. Market Revenue and Forecast (2021-2033)
10.1.6. Polio
10.1.6.1. Market Revenue and Forecast (2021-2033)
10.1.7. Rotavirus
10.1.7.1. Market Revenue and Forecast (2021-2033)
10.1.8. Diphtheria, Pertussis & Tetanus
10.1.8.1. Market Revenue and Forecast (2021-2033)
10.1.9. Influenza
10.1.9.1. Market Revenue and Forecast (2021-2033)
10.1.10. Other Indications
10.1.10.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Pediatric Vaccines Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, By Type (2021-2033)
11.1.2. Market Revenue and Forecast, By Technology (2021-2033)
11.1.3. Market Revenue and Forecast, By Indication (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, By Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, By Technology (2021-2033)
11.1.4.3. Market Revenue and Forecast, By Indication (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, By Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, By Technology (2021-2033)
11.1.5.3. Market Revenue and Forecast, By Indication (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, By Type (2021-2033)
11.2.2. Market Revenue and Forecast, By Technology (2021-2033)
11.2.3. Market Revenue and Forecast, By Indication (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, By Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, By Technology (2021-2033)
11.2.4.3. Market Revenue and Forecast, By Indication (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, By Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, By Technology (2021-2033)
11.2.5.3. Market Revenue and Forecast, By Indication (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, By Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, By Technology (2021-2033)
11.2.6.3. Market Revenue and Forecast, By Indication (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, By Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, By Technology (2021-2033)
11.2.7.3. Market Revenue and Forecast, By Indication (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, By Type (2021-2033)
11.3.2. Market Revenue and Forecast, By Technology (2021-2033)
11.3.3. Market Revenue and Forecast, By Indication (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, By Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, By Technology (2021-2033)
11.3.4.3. Market Revenue and Forecast, By Indication (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, By Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, By Technology (2021-2033)
11.3.5.3. Market Revenue and Forecast, By Indication (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, By Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, By Technology (2021-2033)
11.3.6.3. Market Revenue and Forecast, By Indication (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, By Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, By Technology (2021-2033)
11.3.7.3. Market Revenue and Forecast, By Indication (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, By Type (2021-2033)
11.4.2. Market Revenue and Forecast, By Technology (2021-2033)
11.4.3. Market Revenue and Forecast, By Indication (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, By Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, By Technology (2021-2033)
11.4.4.3. Market Revenue and Forecast, By Indication (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, By Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, By Technology (2021-2033)
11.4.5.3. Market Revenue and Forecast, By Indication (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, By Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, By Technology (2021-2033)
11.4.6.3. Market Revenue and Forecast, By Indication (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, By Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, By Technology (2021-2033)
11.4.7.3. Market Revenue and Forecast, By Indication (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, By Type (2021-2033)
11.5.2. Market Revenue and Forecast, By Technology (2021-2033)
11.5.3. Market Revenue and Forecast, By Indication (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, By Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, By Technology (2021-2033)
11.5.4.3. Market Revenue and Forecast, By Indication (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, By Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, By Technology (2021-2033)
11.5.5.3. Market Revenue and Forecast, By Indication (2021-2033)
Chapter 12. Company Profiles
12.1. Serum Institute of India Pvt. Ltd.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Sanofi Aventis
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CSL Limited
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AstraZeneca Plc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Merck & Co., Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. GlaxoSmithKline Plc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Emergent BioSolutions Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Novavax, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Johnson & Johnson
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample